STOCKS TELEGRAPH

Tag: VXRT Stock Price

  • Vaxart Inc. (VXRT) stock plunged in the current trading session; here’s why

    Vaxart Inc. (VXRT) stock plunged in the current trading session; here’s why

    In the current trading session, Vaxart Inc. (VXRT) stock shares had surged 1.36% to the price of $7.26 at the last check. VXRT stock previously closed the session at $7.36. The VXRT stock volume traded today 13.35 million shares, while in the past 50 days its average volume has been 23.37 million. In the past year up to date, VXRT stock has jumped by 14.29% and in the past week, they have shed by -15.69%.

    What you need to know about Vaxart Inc.

    Vaxart Inc. is a biotech company that is in a clinical stage which means that it is primarily engaged in the discovery and development stage and in phases 1 and 2 of clinical testing. The company focuses on the innovation and discovery of treatments and products relating to oral recombinant protein vaccines. The company has its own oral vaccine platform in which it develops its proprietary discoveries and developments including the projects that are currently in its pipeline. One specific vaccine which is an oral tablet vaccine used for the GI.1 and GII.4 norovirus strains. The vaccine is known as the norovirus vaccine and is currently in the phase 1 stage which is used for testing the safety and dosage of a drug. Another project in the pipeline of the Vaxartcompany is called the seasonal influenza vaccine that is being tested for efficacy in phase 2 clinical trial and as the name suggests it is used for the treatment of Influenza H1 infection. Since the inception of the pandemic, rarely any biotech company specifically one that is focusing on the niche of vaccine does not have a vaccine for coronavirus in its pipeline.  VXRT stock has SARS-CoV2 infection’s treatment vaccine in phase 1 clinical trial for the testing of its safety and dosage. The company has specifically collaborated with Janssen Vaccines & Prevention B.V. for the evaluations of the proprietary oral vaccine platform for Janssen universal influenza vaccine program. The headquarters of the company is established in South San Francisco, California.

    Vaxart is giving licensing for VapendavirTM to Altesa Biosciences

    It is a common marketing strategy and business model adopted by biotechnology firms where they start specializing in administering certain or all stages of clinical trials and regulatory approvals as well as the marketing and commercialization of the products. These Biotech companies partially act as CRO which stands for Contract Research Organizations; they take certain biotech and pharmaceutical projects and drug programs as an outsourcing company on contract and take on the role and responsibility for launching the drug program.

    This has been the case today when it comes to VXRT stock’s proprietary and patent-formulated VapendavirTM which was given as a contract for development and commercialization to Altesa Biosciences Inc. Both companies made the deal today in the form of an exclusive licensing agreement that was given to Altesa Biosciences Inc. from Vaxart. Vaxart although mainly focuses on the production of vaccines, has created VapendavirTM which is a broad spectrum anti-viral that has the potential of saving thousands and millions of lives that are affected from viral infections for which there are no approved antivirals. The company will focus on the production and development of its vaccine pipeline while handing over the reins of development for VapendavirTMto Altesa Biosciences Inc.

  • Why The VXRT Stock Was Up In Afterhours Trading?

    In after-hours trading, last day, Vaxart Inc. (VXRT) gained 5.79% to $8.40 on the charts. Valxart stock rose nearly 1.93% on Thursday to close at $7.94. The VXRT stock fluctuated between $7.60 and $8.00 during regular trading. VXRT stock is rising not because of relevant news but because retail investors are showing an interest in vaccine stocks.

    VXRT is volatile for what reason?

    Using its proprietary delivery system, Vaxart is developing a range of recombinant vaccines for oral administration.

    • Tablets are used for administering VXRT vaccines, making them easy to store and ship without refrigeration and eliminating the risk of needle-stick injuries.
    • VXRT believes that its proprietary tablet vaccine delivery platform is suitable for the delivery of recombinant vaccines, positioning the company to design recombinant vaccines for new indications and to design oral vaccine versions of marketed vaccines.
    • In its current development program, VXRT develops tablet vaccines for prevention of coronaviruses, noroviruses, influenza, and respiratory syncytial virus (RSV).
    • VXRT has also developed a therapeutic vaccine for human papillomavirus (HPV), its first immuno-oncology indication.
    • In addition to filing domestic and international patent applications, Vaxart has designed and developed adenovirus-based oral vaccinations, which use TLR3 agonists.

    More specifically,

    VAXART plans to begin phase 1/2 testing of its variant-specific candidate vaccines in the third quarter and begin phase 2 testing of its oral COVID-19 vaccine candidate within the next few months.

    A few variant-specific candidates will be moved forward into clinical trials this year with the help of Vaxart’s lead oral COVID-19 vaccine candidate. Additionally, the company is embarking on clinical trials for a norovirus vaccine at an early stage.

    A look at VXRT’s performance:

    During the last five days, Vaxart (VXRT) stock has gained 10.74%; however, the stock has gained 16.76% in the past month. In the last three months, VXRT shares rose 19.94%, and so far in 2021, the stock is up 233.22%.